Structure Therapeutics Inc.
GPCR
$54.51
-$0.19-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.99% | 70.13% | 29.45% | 11.78% | 39.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.39% | 58.72% | -129.20% | 60.98% | 111.46% |
| Operating Income | -68.39% | -58.72% | 129.20% | -60.98% | -111.46% |
| Income Before Tax | -72.17% | -62.14% | 191.28% | -93.61% | -136.80% |
| Income Tax Expenses | 68.35% | 93.88% | 25.00% | 17.39% | 162.26% |
| Earnings from Continuing Operations | -72.17% | -62.21% | 190.47% | -93.40% | -136.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.17% | -62.21% | 190.47% | -93.40% | -136.85% |
| EBIT | -68.39% | -58.72% | 129.20% | -60.98% | -111.46% |
| EBITDA | -68.27% | -58.45% | 130.93% | -61.12% | -112.07% |
| EPS Basic | -36.37% | -28.42% | 181.78% | -89.17% | -103.36% |
| Normalized Basic EPS | -36.39% | -28.37% | 235.21% | -89.36% | -103.32% |
| EPS Diluted | -36.37% | -28.42% | 181.78% | -89.17% | -103.36% |
| Normalized Diluted EPS | -36.39% | -28.37% | 235.21% | -89.36% | -103.32% |
| Average Basic Shares Outstanding | 26.24% | 26.31% | 10.63% | 2.24% | 16.47% |
| Average Diluted Shares Outstanding | 26.24% | 26.32% | 10.63% | 2.24% | 16.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |